Voices
Tom Powles: ctDNA Maybe More Useful in Papillary Than Clear Cell RCC
Tom Powles/X

Tom Powles: ctDNA Maybe More Useful in Papillary Than Clear Cell RCC

Tom Powles, Head of Solid Tumor Research at Barts Cancer Institute, shared a post on X:

“Update dated data from CALYPSO (phase 2 Sav+durva in papillary RCC). Here the focus is on ctDNA, Frankie Jackson-Spence shows most patients are positive (informed approach) and dynamic changes occur with therapy which are prognostic. ctDNA maybe more useful in papillary than Clear cell RCC․”

Title: CALYPSO: Final Results of Savolitinib and Durvalumab Combination in Metastatic Papillary Renal Cancer

Authors: Francesca Jackson-Spence, James Larkin, Poulam Patel, Begoña P. Valderrama, Alejo Rodriguez-Vida, Hilary Glen, Fiona C. Thistlethwaite, Christy Ralph, Gopalakrishnan Srinivasan, Maria Jose Mendez-Vidal, Merrida Childress, Wenshu Li, Patrick Boyle, Amaya Gascó, Aleksandra Markovets, Ryan Hartmaier, Charlotte Ackerman, Bernadett E. Szabados, Garima Priyadarshini, Fahmida Jamal, Thomas Powles and Cristina Suárez․

Read the Article

Tom Powles

Other articles featuring Tom Powles on OncoDaily.

Alejo Rodriguez-Vida Aleksandra Markovets Amaya Gascó Barts Cancer Institute Begoña P Valderrama Bernadett E. Szabados CALYPSO cancer Charlotte Ackerman Christy Ralph Clear Cell RCC Cristina Suárez ctDNA Fahmida Jamal Fiona C. Thistlethwaite Francesca Jackson-Spence Frankie Jackson-Spence Garima Priyadarshini Gopalakrishnan Srinivasan Hilary Glen James Larkin Maria Jose Mendez-Vidal Merrida Childress OncoDaily Oncology Patrick Boyle Poulam Patel Ryan Hartmaier Thomas Powles Tom Powles Wenshu Li